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Abstract
Background: Myeloid-derived suppressor cells (MDSCs) are getting increased attention as one of the main regulatory cells
of the immune system. They are induced at sites of inflammation and can potently suppress T cell functions. In the current
study, we demonstrate how activation of TRPV1 vanilloid receptors can trigger MDSCs, which in turn, can inhibit
inflammation and hepatitis.
Methodology/Principal Findings: Polyclonal activation of T cells, following injection of concanavalin A (ConA), in C57BL/6
mice caused acute hepatitis, characterized by significant increase in aspartate transaminase (AST), induction of inflammatory
cytokines, and infiltration of mononuclear cells in the liver, leading to severe liver injury. Administration of cannabidiol
(CBD), a natural non-psychoactive cannabinoid, after ConA challenge, inhibited hepatitis in a dose-dependent manner,
along with all of the associated inflammation markers. Phenotypic analysis of liver infiltrating cells showed that CBD-
mediated suppression of hepatitis was associated with increased induction of arginase-expressing CD11b
+Gr-1
+ MDSCs.
Purified CBD-induced MDSCs could effectively suppress T cell proliferation in vitro in arginase-dependent manner.
Furthermore, adoptive transfer of purified MDSCs into naı ¨ve mice conferred significant protection from ConA-induced
hepatitis. CBD failed to induce MDSCs and suppress hepatitis in the livers of vanilloid receptor-deficient mice (TRPV1
2/2)
thereby suggesting that CBD primarily acted via this receptor to induce MDSCs and suppress hepatitis. While MDSCs
induced by CBD in liver consisted of granulocytic and monocytic subsets at a ratio of ,2:1, the monocytic MDSCs were
more immunosuppressive compared to granulocytic MDSCs. The ability of CBD to induce MDSCs and suppress hepatitis was
also demonstrable in Staphylococcal enterotoxin B-induced liver injury.
Conclusions/Significance: This study demonstrates for the first time that MDSCs play a critical role in attenuating acute
inflammation in the liver, and that agents such as CBD, which trigger MDSCs through activation of TRPV1 vanilloid receptors
may constitute a novel therapeutic modality to treat inflammatory diseases.
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Introduction
Cannabidiol (CBD) is a major non-psychoactive cannabinoid
component of marijuana (Cannabis sativa) [1]. CBD has been shown
to have potent immunosuppressive and anti-inflammatory prop-
erties [2,3,4] and is currently approved for clinical use in some
countries for the treatment of pain in multiple sclerosis (MS)
patients [5]. In addition to MS, CBD has shown promise in several
rodent models of inflammation [6–10]. A single dose of CBD has
been shown to suppress serum TNF-a production induced by
lipopolysaccharide (LPS) in mice and has been found to be
beneficial in murine collagen-induced arthritis by inhibiting IFN-c
production and T cell proliferation [7].
Hepatitis is the inflammation of the liver that can be caused by
various agents such as viruses, chemicals, drugs, alcohol, genetic
factors, or the patient’s own immune system [11]. The
inflammation can be acute, flaring up and then resolving within
a few weeks to months, or chronic, enduring over many years.
Chronic hepatitis may simmer for 20 years or more before causing
significant symptoms related to advanced liver damage such as
cirrhosis (scarring and liver failure), liver cancer, or death.
American liver foundation estimates that one in every 10 people
in North America is afflicted with a liver, biliary or gallbladder
disease.
Hepatitis represents a worldwide health problem in humans for
which pharmacological treatments currently available are not
adequate. Development of new drugs, however, requires proper
animal models relevant to human hepatitis [12]. Majority of the
liver diseases such as viral hepatitis, autoimmune hepatitis (AIH),
primary biliary cirrhosis, primary sclerosing cholangitis, and liver
allograft rejection are caused by activated T lymphocytes that
infiltrate and destroy liver parenchyma leading to liver injury
[13]. Injection of mice with the T-cell mitogenic plant lectin
Concanavalin A (ConA), results in polyclonal activation of T
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which mimics activated T-cell mediated hepatitis [14]. ConA-
induced hepatitis has been well established as an ideal animal
model to study T-cell mediated hepatic injury and has been used
extensively to elucidate various aspects of human T cell-mediated
liver diseases, such as AIH and viral hepatitis [14–20]. It is
characterized by elevated levels of aspartate transaminase (AST)
and alanine transaminase (ALT) enzyme activities, and inflam-
matory cytokines in blood and liver. Histologically, ConA
injection induces dramatic inflammatory infiltrates in the liver,
particularly T cells. In this model, liver injury occurs without
sensitization or priming as compared to other models of liver
inflammation such as galactosamine-lipopolysaccharide (LPS)
induced hepatitis [21].
Myeloid-derived suppressor cells (MDSCs), are a newly
identified suppressor cells of myeloid lineage which co-express
CD11b and Gr-1 antigens [22,23]. These cells, originally
identified in tumor bearing hosts, have been shown to possess
potent suppressive functions and regulate inflammatory
responses [24,25]. Although, cannabidiol is known to be
highly immunosuppressive and anti-inflammatory, its effect
on this important suppressive cell population has not been
investigated.
Autoimmune hepatitis is generally treated with medications
that suppress the immune system, such as prednisone and
azathioprine, although these treatments are not universally
effective and long term side effects exist [26,27]. New treatments,
vaccines, and prevention strategies for hepatitis continue to
emerge. Here, we describe our finding that a single dose of CBD
is effective in significantly suppressing ConA-induced T cell-
mediated hepatic inflammation in mice. Importantly, we have
identified a novel pathway through which CBD suppresses
hepatitis involving the induction of MDSCs in liver following
activation of vanilloid receptor, TRPV1. These observations will
help in developing CBD as a potential drug to treat inflammatory
liver diseases.
Figure 1. Cannabidiol (CBD) attenuates ConA-induced hepatitis in mice. WT mice (n=6) were injected with PBS (control), or ConA (12.5 mg/
kg bd.wt., i.v.) to induce hepatitis. ConA injected mice were administered i.p. with vehicle or CBD at 5, 20 or 50 mg/kg bd.wt. CBD group received CBD
alone at 50 mg/kg. A) Blood was collected at 6, 12, 24 and 48 h and serum aspartate transaminase (AST) was determined by spectrophotometric
assay. Data represent mean 6 SEM from 6 individual mice. The changes in AST levels were analyzed by Student’s t-test (# p,0.01 compared to PBS;
*p,0.05, **p,0.01 compared to ConA+veh). Histological analysis: B. Representative H&E stained liver sections obtained 24 h post ConA injection
in WT mice (original magnification 6100). a) Vehicle and b) CBD alone, show normal tissue morphology; c) ConA+veh shows large necrotic lesion
induced by ConA (arrows); d) ConA+CBD (50 mg/kg bd.wt.) shows less necrosis (arrows) of liver parenchyma. C) Quantification of necrotic lesions as a
percentage of liver parenchyma. Data are mean 6 SEM from 4 mice per treatment. At least five fields were analyzed per section from each liver
sample. PBS and CBD controls did not show any necrotic lesions. Student’s t-test, **p,0.01 compared to ConA.
doi:10.1371/journal.pone.0018281.g001
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Cannabidiol suppresses ConA-induced hepatitis
A single injection of concanavalin-A (ConA) has been shown to
induce hepatitis in mice mimicking the symptoms of human
autoimmune hepatitis [14,16–18]. Acute liver inflammation occurs
within 8–24 h of injecting ConA, with clinical and histological
evidence of hepatitis, elevation of transaminase activities in the
plasma and hepatic inflammatory lesions characterized by massive
leukocyte accumulation and hepatic necrosis. In this study, we
investigated if CBD can be used to treat hepatitis using this model.
WT mice were injected with PBS (vehicle), or ConA to induce
hepatitis. ConA injected mice were administered (i.p.) with vehicle
(ConA+veh group) or different doses of CBD, ranging from 5 mg/
kg to 50 mg/kg body wt (ConA+CBD groups), 5 minutes after
ConA injection. Some mice received CBD alone at the maximum
dose of 50 mg/kg (CBD group). Next, blood was collected at 6, 12,
24 and 48 h and plasma AST (aspartate transaminase) was
determined by spectrophotometry using AST assay kit, as
described [28]. As shown in Fig. 1A, intravenous injection of
ConA resulted in dramatic increase in plasma AST levels over
vehicle control, indicative of acute hepatitis. Increased AST levels
were seen as early as 6 h after ConA injection, reaching a peak
around 12 h and declining thereafter. At 48 h, the plasma AST
reached normal levels. Mice which received both ConA and
cannabidiol (ConA+CBD) showed significantly less plasma AST
activity compared to ConA-injected (ConA+veh) group demon-
strating reduced liver injury upon CBD treatment. Cannabidiol
alone injected at the maximum dose showed AST levels similar to
that of vehicle control at all-time points tested thereby suggesting
that CBD did not mediate any direct hepatotoxic effects.
Histological examination of paraformaldehyde fixed liver
sections was performed. Vehicle and CBD alone injected groups
showed normal tissue morphology and did not show any signs of
liver inflammation. Significant leukocyte infiltration and tissue
necrosis was observed 24 h after ConA-injection (Fig. 1B).
Although, CBD treated groups (ConA+CBD) still had significant
cellular infiltrates, CBD treatment resulted in marked decrease in
liver tissue injury with a significant decrease in necrotic lesions
(Fig.1B, C), thereby corroborating that CBD was very effective in
protecting against ConA-induced autoimmune liver injury.
Cannabidiol suppresses pro-inflammatory cytokines
Several cytokines and chemokines were analyzed in the serum
of mice 12 h after ConA-challenge using multiplex cytokine array
system. This time point was selected because AST levels peak at
around 12 h (Fig. 1A). ConA+veh injection resulted in significant
increase in the levels of proinflammatory cytokines, predominantly
IL-2, TNF-a, IFN-c, IL-6, IL-12(p-40), IL-17, MCP-1 and
eotaxin-1 (CCL11) (Fig. 2A) compared to vehicle control. The
levels of these pro-inflammatory cytokines were significantly
decreased in ConA+CBD mice, demonstrating that CBD
treatment led to effective suppression of multiple inflammatory
cytokines which may afford protection against hepatocellular
damage.
We also determined the levels of mRNA for suppressor of
cytokine signaling 1 and 3 (SOCS-1 and SOCS-3) at an early time
point (2 h) in livers by semi-quantitative RTPCR. Although, there
was no significant difference in SOCS-1 mRNA levels, SOCS-3
was significantly induced in ConA+CBD injected mice when
compared to ConA+veh injected mice (Fig. 2B &C), suggesting a
role for SOCS-3 mediated mechanism in the suppression of
cytokines by CBD during hepatitis.
Analysis of liver infiltrating cells
To understand the cellular mechanisms involved, we isolated
the liver infiltrating cells and subjected them to phenotypic
characterization. While performing these studies, we noted that
the number of T cells or mature macrophages (F4/80
high)d i d
not show any significant change following CBD treatment (data
not shown). However, we noticed a dramatic increase in the
percentage and absolute numbers of cells expressing CD11b
and Gr-1. In-depth analysis revealed that vehicle-treated mice
had significant (,10%) CD11b
+Gr-1
+ in the liver and CBD
treatment alone did not affect this percentage or the absolute
number (Fig. 3A, B). Administration of ConA caused an
increase in both the percentage and absolute number of
CD11b
+Gr-1
+ cells. ConA+CBD treatment caused a further
robust induction of CD11b
+Gr-1
+ cells when compared to
ConA+veh treatment group. We also noted that ConA+CBD
treatment caused a relatively modest increase in CD4
+Foxp3
+
Tregs (Fig. 3C, D) in liver when compared to ConA+veh group
indicating that CBD acts by predominantly inducing
CD11b
+Gr-1
+ cells in liver.
Identifying CD11b
+Gr-1
+ in the liver as MDSCs
Recently, myeloid-derived suppressor cells (MDSCs) that
express CD11b and Gr-1 antigens have been shown to be induced
at sites of inflammation that help down-regulate immune responses
[23,25,29,30–32]. The increased presence of CD11b
+Gr-1
+ cells
in mice with hepatitis suggested that such cells may represent
immunosuppressive MDSCs and that they may play a critical role
in suppressing the acute inflammation and liver injury as
evidenced by the AST levels reaching normal levels by 48 h
(Fig. 1A). Furthermore, CBD may promote the induction of such
cells thereby further protecting the host from acute hepatitis.
In order to characterize the CD11b
+Gr-1
+ cells found in the
liver as MDSCs, we triple-stained the isolated infiltrating cells for
CD11b, Gr-1, and for the expression of intracellular arginase 1
(Arg1), which is one of the characteristic features of MDSCs
(Fig. 4A). We found that CD11b
+Gr-1
+ cells in all groups were
Arg-1
+. However, CD11b
+Gr-1
+ cells from ConA+CBD group
showed increased Arg-1 expression as indicated by higher mean
fluorescence intensity (MFI). There was also a significant increase
in arginase functional activity in infiltrating cells isolated from
livers of ConA+CBD group as compared to ConA+veh group
(Fig. 4B). Immunohistochemistry for Arg-1 expression in liver
sections revealed large number of positively stained cells in
ConA+CBD injected mice (Fig. 4C). Wright-Giemsa staining of
cytospin preparations of Percoll isolated infiltrating liver cells
(Fig. 4D) showed granulocytic type cells with circular nuclei as well
as monocytic type cells in both ConA+veh and ConA+CBD
groups, although the frequency of such cells was higher in
ConA+CBD group.
CBD-induced liver CD11b
+Gr-1
+ MDSCs are
immunosuppressive in vitro and in vivo
To assess the immunosuppressive activity of CD11b
+Gr-1
+
MDSCs induced by CBD in livers, we analyzed them for their
ability to suppress T cell proliferation. To this end, we sorted
CD11b
+Gr-1
+ cells (.90% purity) from the livers of mice injected
with ConA+CBD, irradiated them (2000 rad) and co-cultured at
different ratios with purified syngeneic lymph node T cells in the
presence of mitogen ConA (4 mg/mL) for 48 h. T cell proliferation
was determined by thymidine incorporation during the last 8 h of
culture. CBD-induced CD11b
+Gr-1
+ cells from liver significantly
suppressed T cell proliferation at 100:1 and 10:1 ratios of T cell:
Cannabidiol Ameliorates Autoimmune Hepatitis
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arginase-1 inhibitor (nor-NOHA) was added at the start of the
culture. As can be seen, co-incubation with arginase inhibitor
significantly reversed the suppression of T cell proliferation
induced by MDSCs. Together, these data conclusively demon-
strated that the CD11b
+Gr-1
+ cells found in the livers were
actually immunsuppressive MDSCs.
To further test if CBD-induced MDSCs can suppress liver
injury, we adoptively transferred purified MDSCs into naı ¨ve
mice before challenging them with ConA. Five million
CD11b
+Gr-1
+ cells isolated from livers of ConA+CBD group
were injected into naı ¨ve mice, followed by ConA 12 h later. The
transferred MDSCs were able to significantly protect against
liver injury as indicated by decreased AST levels (Fig. 5B). These
data showed that the CBD-induced MDSCs exhibit immuno-
suppressive functions in vivo and that they can prevent acute liver
injury.
Role of vanilloid receptors (TRPV1) in CBD-mediated
suppression of liver injury
Next, we addressed the mechanism of action of CBD. CBD has
been shown to primarily function through vanilloid receptors
(transient receptor potential vanilloid1, TRPV1) [33,34]. To test
the role of TRPV1 in this model, we used vanilloid receptor
knockout (TRPV1
2/2 or VR1-KO) mice. VR1-KO mice
developed hepatitis in response to ConA as indicated by increase
in AST levels, which was similar to that seen in ConA-injected
wild-type (WT) mice (Fig. 6A). However, unlike in WT mice, CBD
was not able to suppress AST levels in VR1-KO mice, suggesting a
critical role for TRPV1 in mediating the anti-inflammatory
activity of CBD. Moreover, when we enumerated the number of
MDSCs in the liver in this experiment, CBD was able to induce
MDSCs in ConA-injected WT but not VR1-KO mice (Fig. 7B &
C), thereby suggesting that induction of MDSCs by CBD in the
livers of hepatitis mice was dependent on TRPV1 receptors. It was
Figure 2. Analysis of inflammatory cytokines, SOCS1 and SOCS3. A) CBD acts by suppressing pro-inflammatory cytokines in ConA-induced
hepatitis. WT mice (n=6) were injected with PBS or ConA. ConA injected mice were administered with vehicle or CBD (25 mg/kg bd.wt.). CBD group
received CBD alone at 25 mg/kg bd.wt. Blood was collected after 12 h and serum cytokines were determined by Bioplex assay. Error bars represent
mean 6 SEM (n=6). The data were analyzed by Student’s t-test (
##p,0.01 compared to PBS; *p,0.05, **p,0.01 compared to ConA+Veh). B) Semi-
quantitative RT-PCR for SOCS-1 and SOCS-3 in livers 2 h after various treatments in vivo. 18S was used as a loading control. C. The densities of bands
were quantified using gel imaging system (BioRad) and expressed as percentage expression relative to 18S. Student’s t-test, *p,0.05 compared to
ConA.
doi:10.1371/journal.pone.0018281.g002
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lower levels of MDSCs in the liver which was similar in both WT
and VR1-KO mice, suggesting that this response was independent
of TRPV1 receptor.
Analysis of MDSC subsets
The CD11b
+Gr-1
+ MDSCs are known to contain heteroge-
neous mixture of myeloid cells with suppressive function. Recently,
two major subsets of MDSCs have been identified based on the
expression of CD11b, Ly6-G and Ly6-C antigens. Granulocytic
subsets (Gr-MDSC) express both Ly6-G and Ly6-C along with
CD11b (CD11b
+Ly6-G
+Ly6-C
+(int)) while monocytic subsets (Mo-
MDSC) express only Ly6-C and CD11b (CD11b
+Ly6-G
–Ly6-C
+)
[29,35,36]. To identify these subsets, we used mAbs specific to
Ly6-G (clone: 1A8) and Ly6-C (clone: HK1.4). Infiltrating cells
from the liver of CBD-treated hepatitis mice showed significant
frequency of CD11b
+Ly6-G
+Ly6C
+(int) granulocytic and CD11b
+
Ly6-G
–Ly6C
+ monocytic MDSCs in close to 2:1 ratio (Fig. 7A).
These subsets were purified by sorting and used in T cell
proliferation assay to determine their relative suppressive potential.
While both the subsets significantly suppressed T cell proliferation
in vitro (Fig. 7B & C), Mo-MDSCs were highly immunosuppressive
compared to Gr-MDSCs.
CBD attenuates SEB-induced acute liver injury
We sought to see if the suppressive effect of CBD was specific to
ConA-induced liver inflammation or would it work in any other
acute liver inflammation model. To this end, we used Staphylo-
coccal Enterotoxin B (SEB)-induced acute liver inflammation.
Injection of SEB into GalN-sensitized mice led to increased AST
Figure 3. Phenotypic characterization of liver infiltrating cells: CBD treatment of hepatitis increases predominantly CD11b
+Gr-1
+
cell numbers in liver. WT mice were injected with PBS (Veh) or ConA. ConA injected mice were simultaneously administered (i.p.) with vehicle or
CBD (25 mg/kg bd.wt.). CBD group received CBD alone at 25 mg/kg bd.wt. Liver infiltrating cells isolated after 12 h were stained for CD11b and Gr-1,
and analyzed by FACS. Representative flow profiles for each sample showing frequency of CD11b
+Gr-1
+ cells (gated) is shown in panel A. Absolute
numbers of CD11b
+Gr-1
+ cells were calculated from percentages and total cell numbers per liver (B). Cells were also stained and analyzed for Foxp3
+
Tregs (D, E). Data represent mean 6 SEM from 4 mice per treatment. Data were analyzed by Student’s t-test (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0018281.g003
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to decrease the AST levels significantly in a dose dependent
manner, showing that CBD was effective in suppressing liver
inflammation in this model. Moreover, in this model as well, CBD
treatment of hepatitis was associated with significant increase in
the frequency and number of CD11b
+Gr-1
+ MDSCs in liver
(Fig. 8B & C).
Discussion
ConA-induced hepatitis is a well-established model for
hepatitis caused as a consequence of T and NKT cell activation
[14,37]. In the current study we demonstrate for the first time
that CBD, a non-psychoactive cannabinoid, can significantly
reduce ConA-induced inflammation and protect the mice from
acute liver injury, as indicated by marked decrease in plasma
AST levels and necrotic lesions. We observed that a single dose of
CBD as low as 20 mg/kg body weight was effective in this model.
CBD is already approved for clinical use in Canada, in
combination with THC under the trade name Sativex (GW
Pharmaceuticals) to alleviate neuropathic pain, spasticity and
overactive bladder in multiple sclerosis and also prescribed for
cancer patients to reduce nausea and improve appetite [5,38].
CBD is also in clinical trials to reduce schizophrenic symptoms
[39,40]. The daily recommended dose of Sativex is 5 oral sprays
per day which is equivalent to 12.5 mg CBD per day as a long
term treatment. In one of the earliest double-blind studies on
Figure 4. Characterization of MDSCs in liver. Liver infiltrating cells isolated from indicated treatment groups (n=4) were triple-stained for
CD11b, Gr-1 and intracellular arginase 1. Respective histograms (filled) for arginase expression on CD11b
+Gr-1
+ gated cells are shown for each group
with respective MFI (A). Open histograms represent staining control. B) Arginase functional activity was determined by spectrophotometric assay
using lysates of liver infiltrating cells from each group. Data are mean 6 SEM (n=4). Student’s t-test, **p,0.01. C) Immunohistochemistry for arginase
expression in liver sections and D) Morphology of infiltrating liver cells by Wright Giemsa staining (a. Veh, b. CBD, c. ConA+veh, d. ConA+CBD).
doi:10.1371/journal.pone.0018281.g004
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days and epileptic patients received 200–300 mg per day for up
to 4 1/2 months without any signs of toxicity or serious side
effects [41]. The study concluded that CBD was effective as an
anti-epileptic drug or as a potentiating agent for other epileptic
drugs compared to placebo. In another randomized double-blind
controlled study of Huntington disease patients, CBD was given
orally at an average daily dose of 700 mg/day for six weeks,
where it was found neither symptomatically effective nor toxic
relative to placebo [42]. In the current study, we used a single
dose of CBD at 20–50 mg/kg body weight in mice, which
showed significant efficacy in an acute inflammation model. This
dose converts to 1.6–4.1 mg/kg of human equivalent dose (HUD)
based on body surface area normalization (BSA) method [43],
and translates to a single dose of 96–246 mg in an average
individual of 60 kg, which seems to be safe and acceptable dose
based on several previous studies in humans mentioned above.
ConA-induced hepatitis is primarily mediated by activated T
cells and NKT cells, and the induction of hepatitis is associated
with the surge in the production of various pro-inflammatory
cytokines. TNF-a and IFN-c are the first cytokines produced after
ConA injection, and are the most critical in inducing hepatitis as
anti-TNF and anti-IFN-c antibodies confer protection against the
disease [16,44]. We found that CBD treatment resulted in
suppression of various pro-inflammatory cytokines including
TNFa and IFN-c induced by ConA.
The protective effect of SOCS3 in liver inflammation is known
[45]. Replenishing the intracellular stores of SOCS3 with cell
penetrating forms of SOCS3 has been shown to effectively
suppress the devastating effects of acute inflammation in ConA,
LPS or SEB-induced hepatitis models [45]. Attenuated liver injury
in STAT1
–/– and IFN-c
–/– mice in response to ConA was
associated with enhanced SOCS3 activation Whereas, decreased
SOCS3 activation in IL-6
–/– mice seem to result in enhanced
hepatitis in response to ConA [46]. Furthermore, forced
expression of SOCS3 in T cells has been shown to protect against
the development of ConA-induced hepatitis [47]. In the current
study, we observed that CBD induced SOCS-3 in the liver after
ConA challenge which may contribute to suppression of
inflammatory cytokines observed, and decreased liver injury.
CBD treatment caused a dramatic decrease in inflammatory
loci or necrotic lesions in livers of ConA-treated mice. Our
phenotypic analysis and detection of CD11b
+Gr-1
+ cells in livers
showed that majority of the infiltrating cells in the CBD treated
group consisted of MDSCs. MDSCs express arginase which can
metabolize and deplete L-Arginine, an essential amino acid
required for the proliferation and function of T cells. This seems
to be the primary mechanism by which MDSCs suppress activated
T cells [23,30,48]. In the current study, using arginase enzyme
activity assay based on the conversion of L-arginine to L-ornithine,
we demonstrated that CBD-induced MDSCs in liver expressed
functionally active arginase. Purified MDSCs from CBD treated
mice were able to suppress ConA-stimulated T cell proliferation in
vitro in Arg-1 dependent manner. In vivo, the suppressive activity of
adoptively transferred MDSCs could be demonstrated in models
of inflammation [49] and cancer [50]. In the current model, we
showed that the adoptively transferred MDSCs induced by CBD
were able to significantly protect mice from ConA-hepatitis,
thereby conclusively demonstrating that CBD-induced MDSCs
were indeed functional and can suppress hepatitis. It should be
noted that ConA-induced hepatitis by itself showed a small
increase in the number of MDSCs in livers. This may be a natural
mechanism following inflammatory stimuli to regulate inflamma-
tion. Such MDSCs may play a crucial role in helping the host
recover from inflammation as evidenced by the restoration of AST
levels to basal levels by 48 h. Nevertheless, CBD treatment further
triggered the induction of MDSCs which also expressed higher
density of Arg-1. It is interesting to note that CBD alone did not
induce any MDSCs in liver of naı ¨ve mice. We speculate that CBD
triggers the induction of MDSCs only when there is an insult or
inflammation in the liver.
Cannabidiol has been shown to bind and function primarily
through TRPV1 or vanilloid receptors [33,34]. Vanilloid receptors
Figure 5. CBD-induced MDSCs in liver are immunosuppressive
in vitro and in vivo. CD11b
+Gr-1
+ cells from liver infiltrating cells of
ConA+CBD injected mice were purified, irradiated and co-cultured at
different ratios with naı ¨ve syngenic purified T cells in the presence of
mitogen ConA (4 mg/mL) for 48 h. T cell proliferation was determined
by [3H]thymidine incorporation during the last 8 h of culture. In some
wells with T cell: MDSC ratio of 10:1, arginase-1 inhibitor (nor-NOHA)
was added at the start of the culture at a concentration of 100 mM. Data
are mean 6 SEM of triplicate determinations and representative of two
independent experiments. (B) WT mice (n=4) were injected with
vehicle or ConA. Five million purified CD11b
+Gr-1
+ cells isolated from
livers of ConA+CBD group, were adoptively transferred 12 h before
injecting ConA. Blood was collected 12 h post-ConA injection and
analyzed for AST. Data represent mean 6 SEM from 4 mice per
treatment. Student’s t-test (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0018281.g005
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inflammation [34]. TRPV1 ion channels also mediate the
response to painful heat, extracellular acidosis, and capsaicin,
the pungent compound from plants which upon prolonged use
decreases TRPV1 activity by a phenomenon called desensitization
[51]. CBD possesses no, or very weak affinity for the central and
peripheral canabbinoid receptors (CB1 and CB2) and is not
psychoactive [33,52]. Use of vanilloid receptor knock-out mice in
our study clearly showed that CBD induced suppression of
inflammation in ConA-hepatitis was dependent on TRPV1, so
was the induction of MDSCs by CBD in the livers of ConA-
injected mice. Recently, we demonstrated that activation of
cannabinoid receptors can trigger massive induction of immuno-
suppressive MDSCs [53]. We noted this was dependent on the
production of G-CSF. In the current study, we tested if some
specific chemokine or cytokine may be involved in TRPV1-
mediated induction or accumulation of MDSCs by CBD in liver.
Our attempt to identify such factor, particularly looking at GM-
CSF, G-CSF, and KC by ELISA was not conclusive (data not
shown). Even though there was a significant increase in G-CSF
24 h after CBD treatment of hepatitis corresponding with increase
in number of MDSCs in liver as well as decrease in liver enzymes
(inflammatory marker), blocking studies with anti-G-CSF Ab
failed to reverse the CBD effect.
Finally, we showed that CBD-induced suppression of acute liver
inflammation is not specific to ConA-induced hepatitis, but it is
also equally effective in other acute hepatitis models such as
sensitization with GalN followed by induction of liver inflamma-
tion by sub lethal doses of SEB. Overall, the current study
demonstrates that MDSCs may play a critical role in protecting
the liver from acute inflammation. The most interesting
observation in this study was robust induction of CD11b
+Gr-1
+
MDSCs by CBD in the livers of ConA-induced mice that were
immunosuppressive, which protected mice from hepatitis upon
adoptive transfer. Moreover, CBD was found to induce MDSCs
following activation of TRPV1 inasmuch as, CBD failed to trigger
MDSCs in the livers of TRPV1 deficient mice and failed to protect
them from hepatitis. Together, these studies not only demonstrate
that CBD can protect the host from acute liver injury but also
provide evidence for the first time that MDSCs may play a critical
role in protecting the liver from acute inflammation. Non-
psychoactive cannabinoids such as CBD possess great therapeutic
potential in treating various inflammatory liver diseases, including
autoimmune hepatitis.
Materials and Methods
Mice
Female C57BL/6 mice (8–12 weeks) were obtained from
National Cancer Institute (Frederick, MD). Female vanilloid
receptor knockout (TRPV1) mice on BL/6 background were
purchased from the Jackson labs (Bar Harbor, ME, USA).
Ethics Statement
Mice were housed and maintained under specific pathogen-free
conditions in the Animal Resource Facility of University of South
Carolina and all experiments were pre-approved by the Institu-
tional Animal Care and Use Committee (ICAUC approval
number AUP # 1620).
Reagents
Cell culture grade concanavalin A was from Sigma-Aldrich (St.
Louis, MO). The monoclonal antibodies (mAb), FITC-conjugated
anti-CD11b and anti-Ly6-C (clone: HK1.4), PE-conjugated anti-
CD3, anti-Gr-1 and anti-F4/80, AlexaFlour647-conjugated
CD11b, and purified anti-CD16/CD32 were from eBioscience.
PE-conjugated anti-Ly6-G (clone: IA-8) was from BD Bioscience.
Cannabidiol was provided by NIDA, NIH. N
v-hydroxy-nor-
Arginine (nor-NOHA) was obtained from Cayman Chemical
Company. Cell culture reagents including RPMI 1640 medium
were from Invitrogen Corp. All other reagents and chemicals used
were from Sigma-Aldrich.
Induction of hepatitis and treatment with cannabidiol
Concanavalin A was dissolved in pyrogen-free PBS at a
concentration of 2.5 mg/ml and injected intravenously at a
dose of 12.5 mg/kg body weight to induce hepatitis as
described [54]. Mice were administered intraperitoneally with
indicated doses of cannabidiol (DMSO stock diluted in PBS + a
drop of Tween-80) or vehicle (DMSO similarly diluted in PBS)
5 min after ConA injection. One group received cannabidiol
alone. Blood was collected after 6, 12, 24 and 48 h by retro-
orbital bleeding and sera were separated and stored below
220uCu n t i lf u r t h e ru s e .
Figure 6. Role of TRPV1 (vanilloid) receptors. WT or TRPV1 vanilloid receptor knockout (VR1-KO) mice were injected with vehicle, CBD,
ConA+veh or ConA+CBD. A) After 16 h, blood was collected and serum AST levels were measured. B) Liver infiltrating leukocytes were stained and
analyzed for CD11b
+Gr-1
+ MDSCs by FACS. Representative dot plots with percentage of MDSCs shown (gated). C) Absolute number of MDSCs in the
liver of WT and VR1-KO mice. Data are mean 6 SEM with 4 mice per treatment. **p,0.01, ***p,0.001, n.s. (not significant) based on Student’s t-test.
doi:10.1371/journal.pone.0018281.g006
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Liver enzyme aspartate transaminase activity in sera from
individual mice obtained at various time points after ConA
injection was measured at 340 nm by spectrophotometric method
using a commercially available AST assay kit (Pointe Sci.), as
described previously [54].
Liver histology
After 48 h of post ConA-injection, livers were harvested,
carefully rinsed with PBS and fixed in 4% paraformaldehyde.
Fixed liver tissue was embedded in paraffin, cut into 5 mm thick
sections, deparaffinized in xylene, and serially dehydrated in
decreasing concentrations of ethanol. Sections were stained with
hematoxylin-eosin (H&E) and examined under light microscopy to
evaluate and liver damage. Area of necrotic lesions as a percentage
of total liver parenchyma was quantified using NIH ImageJ
software. At least five fields per section were analyzed from each
liver sample.
Cytokine analysis
Serum obtained 12 h after ConA-injection was used for
analyzing 23 different cytokines and chemokines including IL-2,
TNF-a, IFN-c, IL-1a, IL-1b, IL-3, IL-4, IL5, IL-6, IL-10, IL-
12p40, IL-12p70, IL-17, GM-CSF, G-CSF, KC, MIP-1a,
RANTES and eotaxin-1 by Bioplex cytokine array system
(BioRad).
Reverse Transcription-PCR (RT-PCR)
RT-PCR was performed by standard protocol. The total RNA
was prepared using RNeasy kit (QIAGEN), and cDNA was
Figure 7. Identification of MDSC subsets induced by CBD in liver and their suppressive activity. Liver infiltrating cells were isolated from
ConA+CBD injected mice at 12 h. Cells were triple-stained for CD11b, Ly6-G and Ly-6C, and analyzed by FACS. A) Cells were gated for CD11b
+
expression (histogram) and further analyzed for Ly6-G and Ly6-C antigens (dot plot). Representative dot plot shows percentages of CD11b
+Ly6-
G
+Ly6-C
+ granulocytic MDSCs (Gr-MDSC) and CD11b
+Ly6-G
–Ly6-C
+ monocytic MDSCs (Mo-MDSC). B & C) MDSC subsets were purified by FACS sorting
and used in T cell proliferation assay in vitro at different ratios with syngenic purified T cells stimulated with ConA. T cell proliferation was assessed by
[3H]thymidine incorporation at 48 h. T cells cultured without MDSCs and with ConA served as the positive control. Data are mean 6 SEM for triplicate
determinations and representative of two separate experiments. **p,0.01, ***p,0.001, based on Student’s t test.
doi:10.1371/journal.pone.0018281.g007
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specific primers used for amplification were: SOCS-1 (forward 59
GAG GTC TCC AGC CAG AAG TG 39 and reverse 59 CTT
AAC CCG GTA CTC CGT GA 39), SOCS-2 (forward 59 AAG
ACA TCA GCC GGG CCG ACT A 39 and reverse 59 GTC
TTG TTG GTA AAG GTA GTC 39), 18S (forward 59 GCC
CGA GCC GCC TGG ATA C 39 and reverse 59 CCG GCG
GGT CAT GGG AAT AAC 39). 18S served as the internal
control. The PCR products were electrophoresed on 1.5% agarose
gel in the presence of ethidium bromide and visualized in a gel
imaging system (BioRad). The densities of bands were analyzed
with NIH Image J software and normalized to internal control.
Cell preparation and flow cytometric analysis
Liver infiltrating cells were isolated using Percoll density
separation. Briefly, single cell suspensions from livers were
prepared by using a tissue homogenizer and passing the
homogenate through sterile nylon mesh (70 mM). Cell suspension
was washed once with PBS and pellet suspended in 33% Percoll
(Sigma-Aldrich) diluted in sterile PBS and centrifuged at 2000 rpm
for 15 min at 25uC. Leukocyte cell pellet was washed twice with
PBS. Contaminating RBCs were lysed using RBC-lysis solution.
For FACS analysis, cells were blocked using mouse Fc-block (anti-
CD16/CD32) and stained for various cell surface markers using
fluorescently labeled mAb (10 mg/mL, in PBS containing 2%
Figure 8. CBD attenuates SEB-induced acute liver injury by inducing MDSCs in liver. WT mice (n=6) were sensitized by injecting D-
galactosamine (GalN), 20 mg/mouse in 100 mL PBS (i.p.). After 15 min, SEB was injected (40 mg/mouse, in 100 mL PBS, i.p.). For treatment groups, 10 or
50 mg/kg bd.wt. of CBD was administered i.p. A) Blood was collected at 8 h post SEB injection and serum AST levels were measured. Student’s t-test
(
#p,0.01 compared to Veh/GalN control; *p,0.05, **p,0.01 compared to GalN/SEB). B. Histology: Liver samples after 48 h were fixed and
embedded in paraffin. Five mm sections were stained by H&E and analyzed by light microscopy. Representative photomicrographs are shown. a) Veh/
GalN, b) CBD50, c) GalN/SEB and d) GalN/SEB+CBD50 (CBD50 =50 mg/kg). Liver infiltrating cells from the treatment groups as indicated were
isolated at 24 h and stained for CD11b and Gr-1 and analyzed by flow cytometry (CBD25=25 mg/kg). Representative dot plots are shown with
percentages of CD11b
+Gr-1
+ MDSCs (C). D) Absolute number of MDSCs in liver for each group (n=4). Student’s t-test (**p,0.01 compared to GalN/
SEB).
doi:10.1371/journal.pone.0018281.g008
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cytometer (FC500, Beckman Coulter). Only live cells were
counted by setting gates on forward and side scatters to exclude
cell debris and dead cells. Cells stained similarly with isotype
antibodies served as staining controls to set the voltage. Data
obtained were analyzed in Cytomics CXP software (Beckman
Coulter).
Arginase Activity Assay
Cell lysates were obtained by suspending the cell pellet in lysis
buffer (50 mM HEPES, 150 mM NaCl, 5 mM EDTA, 1 mM
NaVO4, and 0.5% Triton X-100) containing 50 mg/ml aprotinin,
50 mg/ml leupeptin, 100 mg/ml trypsin-chymotrypsin inhibitor,
and 2 mM PMSF. Lysates were centrifuged at 30006g for 10 min
at 4uC. Protein content was determined by BCA method (Sigma-
Aldrich) and cell lysates (5 mg) were tested for arginase activity by
measuring the production of L-ornithine. Briefly, cell lysates were
added to 25 mL of Tris-HCl (50 mM; pH 7.5) containing 10 mM
MnCl2. This mixture was heated at 55–60uC for 10 min to
activate arginase. Then, a solution containing 150 mL carbonate
buffer (100 mM) and 50 mL L-arginine (100 mM) was added and
incubated at 37uC for 20 min. The hydrolysis reaction from L-
arginine to L-ornithine was identified by a colorimetric assay after
the addition of ninhydrin solution and incubation at 95 uC for 1 h.
Wright-Giemsa staining
Cells were collected by cytospin onto glass slides and dried
completely for 30 min. Slides were then stained with Wright-
Giemsa stain (Fisher Sci.) according manufacturer’s instructions
and analyzed by light microscopy.
Cell sorting
Mice were injected with ConA (12.5 mg/kg) + CBD (25 mg/
kg). Liver infiltrating cells were isolated after 12–16 h by Percoll
separation. Cells were blocked using Fc-block and stained using
appropriate mAb. CD11b
+Gr-1
+ cells (MDSCs), CD11b
+Ly6-
G
+Ly-6C
+ granulocytic (Gr-MDSC) and CD11b
+Ly6-G
2Ly-6C
+
monocytic (Mo-MDSC) subsets were sorted to .90% purity using
FACS Aria (BD Biosci.) after labeling with appropriate fluores-
cently conjugated mAbs.
T cell proliferation assay
Purified MDSCs were irradiated at approximately 2000 rads
and cultured at different ratios with purified syngenic T cells
(2610
5) stimulated with ConA (4 mg/ml) in a 96-well round
bottom plates, in complete RPMI 1640 medium (Invitrogen)
supplemented with 10% FBS, 10 mM HEPES, 1 mM penicillin-
streptomycin, and 50 mM b-mercaptoethanol. T cell proliferation
was determined after 48 h culture by pulsing with [3H]thymidine
(2 mCi/well) during the final 8 h of culture. Cultures were
harvested using a cell harvester and thymidine incorporation
was measured in a beta counter (Perkin Elmer).
Adoptive transfer experiments
ConA was injected into naı ¨ve C57BL/6 (WT) mice to induce
hepatitis as described before. For adoptive transfer, purified
CD11b
+Gr-1
+ MDSCs from the livers of ConA+CBD injected
mice were transferred to a group of naı ¨ve mice (5610
6 purified
MDSCs/mouse, i.v) 12 h before injecting ConA. Blood was
collected 12 h after ConA challenge. Hepatitis was assessed by
measuring liver enzyme aspartate transaminase (AST) in sera.
Statistical Analysis
Data are expressed as mean 6 S.E.M. Student’s t-test was used
for comparison and P#0.05 was considered statistically significant.
Experiments were repeated at least twice unless otherwise
mentioned.
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